Ifenprodil, sold under the brand names Cerocral, Dilvax, and Vadilex, is a cerebral vasodilator that has been marketed in some countries, including in Japan, Hong Kong, and France. It is currently under development for treatment of a variety of additional indications. Ifenprodil has multiple known pharmacological actions. It is an inhibitor of the NMDA receptor, specifically of NMDA receptors containing GluN1 and GluN2B subunits, the "ifenprodil binding site". Additionally, ifenprodil inhibits GIRK channels and interacts with α1-adrenergic, serotonin, and sigma receptors. Chemically, ifenprodil is a substituted phenethylamine and β-hydroxyamphetamine derivative. It is used pharmaceutically as the tartrate salt.

Research

Ifenprodil has been studied as a possible medication to prevent tinnitus after acoustic trauma. It is currently in phase II trials for cough and idiopathic pulmonary fibrosis, among other investigational uses.